Pharmacotherapy of cognitive deficits in schizophrenia.
While second-generation antipsychotics treat negative as well as positive symptoms, recovery for persons with schizophrenia remains elusive, in part because there are no FDA-approved medications that treat the cognitive deficits of schizophrenia (CDS). Recent work has identified agents that, when added to antipsychotics, improve cognition in schizophrenia. This work and hypothesized mechanisms of action will be reviewed.
1 Department of Psychiatry, Columbia University Medical Center, New York, New York, USA.
Lewis A
LA
Opler
1 Department of Psychiatry, Columbia University Medical Center, New York, New York, USA.
Alice
A
Medalia
2 Department of Psychiatry, New York University School of Medicine, New York, New York, USA.
Mark G
MG
Opler
3 Department of Psychiatry, University of California, San Diego, La Jolla, California, USA.
Stephen M
SM
Stahl
D001921:Brain / Q000187:drug effects / Q000473:pathology; D003072:Cognition Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology* / Q000473:pathology; D017277:Drug Approval; D006801:Humans; D008954:Models, Biological; D009474:Neurons / Q000187:drug effects / Q000378:metabolism; D009483:Neuropsychological Tests; D011619:Psychotropic Drugs / Q000627:therapeutic use*; D017982:Receptors, Biogenic Amine / Q000378:metabolism; D012559:Schizophrenia / Q000150:complications*; D009435:Synaptic Transmission / Q000187:drug effects / Q000502:physiology
D011619:Psychotropic Drugs; D017982:Receptors, Biogenic Amine